JERUSALEM, Feb. 10, 2021 /PRNewswire/ -- BiondVax
Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical
company focused on developing, manufacturing and ultimately
commercializing products for the prevention and treatment of
infectious diseases and related illnesses, today announced that the
underwriter of its recent follow-on underwritten offering fully
exercised its over-allotment option to purchase 365,217 of
BiondVax's American Depositary Shares ("ADS"). The option was
granted in connection with the follow-on offering of 2,434,783 ADSs
at a public offering price of $4.95
per ADS which closed on February 2,
2020.
The exercise of the over-allotment option brings the total gross
proceeds of the offering to approximately $13.8 million.
Aegis Capital Corp. acted as sole bookrunning
manager for the offering.
The ADSs described above were offered by the Company pursuant to
a registration statement that was previously filed with the
Securities and Exchange Commission (the "SEC") and declared
effective by the SEC on August 10,
2020. A prospectus supplement and accompanying base
prospectus relating to and describing the final terms of the
offering are available on the SEC's website located at
www.sec.gov or from Aegis Capital Corp., Attention: Syndicate
Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at
syndicate@aegiscap.com, or by telephone at (212) 813-1010.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such jurisdiction.
About BiondVax
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a
biopharmaceutical company focused on developing, manufacturing and
ultimately commercializing products for the prevention and
treatment of infectious diseases and related illnesses. The Company
had been developing M–001, a novel influenza vaccine candidate that
was designed to provide multi-strain and multi-season protection
against current and future seasonal and pandemic influenza. In
seven Phase 1/2 and Phase 2 clinical trials designed to test for
immunogenicity, the Company was able to demonstrate M-001 was
effective in stimulating an immune response to a broad range of
influenza virus strains. In October
2020, the Company completed a Phase 3 clinical trial of
M–001 which failed to meet the trial's primary and secondary
efficacy endpoints. The Company is now pursuing opportunities in
the infectious disease space, including exploring several
alternatives for development of a pipeline of assets.
Contact Details
Joshua E. Phillipson |
+972 8 930 2529 | j.phillipson@biondvax.com
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Litigation Reform Act of 1995. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements, including statements regarding
future business strategies that BiondVax may explore. These
forward-looking statements reflect management's current views with
respect to certain current and future events and are subject to
various risks, uncertainties and assumptions that could cause the
results to differ materially from those expected by the management
of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include,
but are not limited to, the risk that BiondVax may not be able to
secure additional capital on attractive terms, if at all; the risk
that the European Investment Bank may accelerate the loans under
its finance contract with BiondVax; the risk that BiondVax may not
execute a strategic alternative to M-001 and, if executed, may not
be successful; risks relating to the COVID-19 (coronavirus)
pandemic; BiondVax's ability to acquire rights to additional
product opportunities; BiondVax's ability to enter into
collaborations on terms acceptable to BiondVax or at all;
timing of receipt of regulatory approval of BiondVax's
manufacturing facility in Jerusalem, if at all or when required; and the
risk that drug development involves a lengthy and expensive process
with uncertain outcomes. More detailed information about the risks
and uncertainties affecting the Company is contained under the
heading "Risk Factors" in our prospectus supplement, which is
available on the SEC's website, www.sec.gov. BiondVax undertakes no
obligation to revise or update any forward-looking statement for
any reason.
View original
content:http://www.prnewswire.com/news-releases/biondvax-announces-exercise-in-full-of-underwriters-over-allotment-option-in-follow-on-offering-301226172.html
SOURCE BiondVax Pharmaceuticals Ltd.